SEAMARK: Randomized phase 2 study of pembrolizumab plus encorafenib plus cetuximab vs pembrolizumab alone for first-line treatment of BRAF V600E-mutant microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC)

by on 22 de gener de 2024 with No hi ha comentaris
  • Kopetz, S., Bekaii-Saab, T. S., Yoshino, T., Chung, C. H., Zhang, X. S., Tabernero, J. (2023). SEAMARK: Randomized phase 2 study of pembrolizumab plus encorafenib plus cetuximab vs pembrolizumab alone for first-line treatment of BRAF V600E-mutant microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC). Journal of Clinical Oncology, 41 (4), TPS268-TPS268.

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *